Model NO.: 167933-07-5
Category: Other Pharmaceutical Intermediate
Trademark: Biocar
Transport Package: Foil Bag or Drums
Specification: 10g, 1kg
Origin: Wuhan, Hubei, China
HS Code: 0000000000
Model NO.: 167933-07-5
Category: Other Pharmaceutical Intermediate
Trademark: Biocar
Transport Package: Foil Bag or Drums
Specification: 10g, 1kg
Origin: Wuhan, Hubei, China
HS Code: 0000000000
Higher Quality Only for Export Flibanserin Dosage Usage and Effect
Basic Info.
| Product Name: |
Flibanserin |
| Synonyms: |
Flibanserin;Bimt 17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one;Filbanserin;Flibanerins;1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one;BIMT 17BS;Flibanserin(BIMT17) |
| CAS: |
167933-07-5 |
| MF: |
C20H21F3N4O |
| MW: |
390.4 |
Flibanserin,a drug used to improve the female sexual desire, which can reduce the serotonin inhibit sexual desire, to improve the level of sexual stimulant dopamineÂ
| Other Pharmaceutical Intermediate |
| Flibanserin/Bimt 17/ |
167933-07-5 |
Flibanserin HCl |
147359-76-0 |
| Bimt-17-BS/Girosa |
| Bimatoprost |
155206-00-1 |
Latanoprost |
130209-82-4 |
| Corey lactone |
69222-61-3Â |
Tianeptine Sodium |
30123-17-2 |
| Tadalafil |
171596-29-5 |
Vardenafil |
224785-90-4 |
| Ketoconazole |
65277-42-1 |
Fluconazole |
86386-73-4 |
| Terbinafine Hydrochloride |
78628-80-5 |
Miconazole nitrate |
22832-87-7 |
| Cyproheptadine hydrochloride |
41354-29-4 |
Minoxidil |
38304-91-5 |
Flibanserin character:
Flibanserin is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain.
Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low
Flibanserin usage and dosage:
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had "satisfying sexual events". In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of "satisfying sexual events" from 2.7 to 3.7 times a month. The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
Flibanserin Application:
HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related , psychiatric (e.g., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to a complex interplay of these factors.
Â
Flibanserin is a novel, nonhormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.
Â
Higher Quality Only for Export Flibanserin Dosage Usage and Effect
Basic Info.
| Product Name: |
Flibanserin |
| Synonyms: |
Flibanserin;Bimt 17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one;Filbanserin;Flibanerins;1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one;BIMT 17BS;Flibanserin(BIMT17) |
| CAS: |
167933-07-5 |
| MF: |
C20H21F3N4O |
| MW: |
390.4 |
Flibanserin,a drug used to improve the female sexual desire, which can reduce the serotonin inhibit sexual desire, to improve the level of sexual stimulant dopamineÂ
| Other Pharmaceutical Intermediate |
| Flibanserin/Bimt 17/ |
167933-07-5 |
Flibanserin HCl |
147359-76-0 |
| Bimt-17-BS/Girosa |
| Bimatoprost |
155206-00-1 |
Latanoprost |
130209-82-4 |
| Corey lactone |
69222-61-3Â |
Tianeptine Sodium |
30123-17-2 |
| Tadalafil |
171596-29-5 |
Vardenafil |
224785-90-4 |
| Ketoconazole |
65277-42-1 |
Fluconazole |
86386-73-4 |
| Terbinafine Hydrochloride |
78628-80-5 |
Miconazole nitrate |
22832-87-7 |
| Cyproheptadine hydrochloride |
41354-29-4 |
Minoxidil |
38304-91-5 |
Flibanserin character:
Flibanserin is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain.
Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low
Flibanserin usage and dosage:
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had "satisfying sexual events". In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of "satisfying sexual events" from 2.7 to 3.7 times a month. The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
Flibanserin Application:
HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related , psychiatric (e.g., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to a complex interplay of these factors.
Â
Flibanserin is a novel, nonhormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.
Â